NCT04503603View on ClinicalTrials.gov

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

December 23, 2020

Study Completion Date

December 23, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

Lanadelumab

Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.

OTHER

Placebo

Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Takeda

INDUSTRY